Real-world Effectiveness Evaluation of Budesonide/formoterol Spiromax for the Management of Asthma and Chronic Obstructive Pulmonary Disease in the UK

Overview

Journal BMJ Open

Specialty General Medicine

Date 2018 Oct 29

PMID 30368448

Citations 1

Authors

Jaco Voorham

Nicolas Roche

Hicham Benhaddi

Marianka van der Tol

Victoria Carter

Job F M van Boven

Leif Bjermer

Marc Miravitlles

David B Price

Affiliations

Soon will be listed here.

Abstract

Objectives: Budesonide/formoterol (BF) Spiromax is an inhaled corticosteroid/long-acting β-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We evaluated non-inferiority of BF Spiromax after changing from another FDC inhaler, compared with continuing the original inhaler.

Methods: Patients with asthma and/or COPD who switched to BF Spiromax were matched (1:3) with non-switchers. Data were obtained from the Optimum Patient Care Research Database and Clinical Practice Research Datalink in the UK. The primary end point was the proportion of patients achieving disease control (using the risk domain control (RDC) algorithm); secondary end points were: exacerbation rate, short-acting β-agonist (SABA) use and treatment stability (achieved RDC; no maintenance treatment change). Non-inferiority was defined as having 95% CI lower bound above -10%, using conditional logistic regression and adjusted for relevant confounders.

Results: Comparing 385 matched patients (asthma 253; COPD 132) who switched to BF Spiromax with 1091 (asthma 743; COPD 348) non-switchers, non-inferiority of BF Spiromax in RDC was demonstrated (adjusted difference: +6.6%; 95% CI -0.3 to 13.5). Among patients with asthma, switchers to BF Spiromax versus BF Turbuhaler reported fewer exacerbations (adjusted rate ratio (RR) 0.76;95% CI 0.60 to 0.99; p=0.044); were less likely to use high daily doses of SABA (adjusted OR 0.71;95% CI 0.52 to 0.98; p=0.034); used fewer SABA inhalers (adjusted RR 0.92;95% CI 0.86 to 0.99; p=0.019); and were more likely to achieve treatment stability (adjusted OR 1.44;95% CI 1.02 to 2.04; p=0.037). No significant differences in these end points were seen among patients with COPD.

Conclusions: Among UK patients with asthma and COPD, real-world use of BF Spiromax was non-inferior to BF Turbuhaler in terms of disease control. Among patients with asthma, switching to BF Spiromax was associated with reduced exacerbations, reduced SABA use and improved treatment stability versus continuing on BF Turbuhaler.

Citing Articles

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.

de Simon Gutierrez R, Castro R Curr Allergy Asthma Rep. 2022; 22(11):151-161.

PMID: 36087251 PMC: 9532287. DOI: 10.1007/s11882-022-01041-2.

References

Herland K, Akselsen J, Skjonsberg O, Bjermer L . How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med. 2005; 99(1):11-9. DOI: 10.1016/j.rmed.2004.03.026. View

Price D, Brusselle G, Roche N, Freeman D, Chisholm A . Real-world research and its importance in respiratory medicine. Breathe (Sheff). 2015; 11(1):26-38. PMC: 4487388. DOI: 10.1183/20734735.015414. View

Stuart E, Ialongo N . Matching methods for selection of subjects for follow-up. Multivariate Behav Res. 2011; 45(4):746-765. PMC: 3017384. DOI: 10.1080/00273171.2010.503544. View

Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F . Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J. 2013; 22(4):439-48. PMC: 6443103. DOI: 10.4104/pcrj.2013.00088. View

Crane M, Jenkins C, Goeman D, Douglass J . Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. NPJ Prim Care Respir Med. 2014; 24:14034. PMC: 4373405. DOI: 10.1038/npjpcrm.2014.34. View

Israel E, Roche N, Martin R, Colice G, Dorinsky P, Postma D . Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in Asthma. Ann Am Thorac Soc. 2015; 12(6):798-806. DOI: 10.1513/AnnalsATS.201412-580OC. View

Broeders M, Sanchis J, Levy M, Crompton G, Dekhuijzen P . The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009; 18(2):76-82. PMC: 6619237. DOI: 10.4104/pcrj.2009.00025. View

Doyle S, Lloyd A, Williams A, Chrystyn H, Moffat M, Thomas M . What happens to patients who have their asthma device switched without their consent?. Prim Care Respir J. 2010; 19(2):131-9. PMC: 6602231. DOI: 10.4104/pcrj.2010.00009. View

Bosnic-Anticevich S, Sinha H, So S, Reddel H . Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma. 2010; 47(3):251-6. DOI: 10.3109/02770900903580843. View

10.

Azouz W, Chetcuti P, Hosker H, Saralaya D, Chrystyn H . Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm Med. 2015; 15:47. PMC: 4450517. DOI: 10.1186/s12890-015-0043-x. View

11.

Calverley P . Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 1(3):161-6. DOI: 10.1513/pats.200402-008MS. View

12.

Masoli M, Fabian D, Holt S, Beasley R . The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59(5):469-78. DOI: 10.1111/j.1398-9995.2004.00526.x. View

13.

Price D, Roman-Rodriguez M, McQueen R, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K . Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017; 5(4):1071-1081.e9. DOI: 10.1016/j.jaip.2017.01.004. View

14.

Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017; 49(3). DOI: 10.1183/13993003.00214-2017. View

15.

Thomas M, Pavord I . Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we?. Prim Care Respir J. 2012; 21(1):8-10. PMC: 6547900. DOI: 10.4104/pcrj.2012.00022. View

16.

Sandler N, Hollander J, Langstrom D, Santtila P, Saukkonen A, Torvinen S . Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler). BMJ Open Respir Res. 2016; 3(1):e000119. PMC: 4809147. DOI: 10.1136/bmjresp-2015-000119. View

17.

Huitfeldt B, Hummel J . The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians. Pharm Stat. 2011; 10(5):414-9. DOI: 10.1002/pst.508. View

18.

Barbara S, Kritikos V, Bosnic-Anticevich S . Inhaler technique: does age matter? A systematic review. Eur Respir Rev. 2017; 26(146). PMC: 9489120. DOI: 10.1183/16000617.0055-2017. View

19.

Dolovich M, Ahrens R, Hess D, Anderson P, Dhand R, Rau J . Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127(1):335-71. DOI: 10.1378/chest.127.1.335. View

20.

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E . Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2016; 5(2):020415. PMC: 4693508. DOI: 10.7189/jogh.05.020415. View